Although TNFα has been accepted as a mediator of cancer cachexia for many years, TNFα inhibitors (both a recombinant fusion protein of TNFα type II receptor which blocks TNFα activity or a recombinant anti-TNFα antibody) have not demonstrated meaningful clinical benefits with respect to reductions in muscle wasting or restorations of lean body mass (Miyamoto et al. 2016). Here, TNF is linked to cancer.